Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals' stock has experienced several notable events in the past six months. The stock's 52-week high was $9.82 and its 52-week low was $3.28. Verrica Pharmaceuticals reported strong financial results in Q3 2025, with an EPS of $0.13 and quarterly revenue of $14.34 million. Analyst ratings are mixed, with a downgrade to "Hold" by Wall Street Zen, but upgrades to "Strong-Buy" by Zacks Research and "Buy" ratings from other firms. Over the last three months, insiders purchased 4,236,346 shares of company stock worth approximately $17,962,107. Several institutional investors modified their holdings, with Bridgeway Capital Management LLC and Legacy Trust acquiring new positions in Q3 and Q4 2025, respectively.

Demand for Verrica Pharmaceuticals' products, specifically YCANTH®, has shown some seasonality. In Q3 2025, the sequential growth in dispensed applicator units slowed to 5% from the prior quarter's 32.8% growth, which was attributed to seasonality. A seasonal analysis of VRCA stock over the past 7 years suggests a potential "Buy Date of December 19 and a Sell Date of April 6," which has historically resulted in a geometric average return of 12.64% above the S&P 500 Total Return Index.

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company focused on developing and commercializing pharmaceutical products for skin diseases requiring medical interventions. Their primary product is YCANTH®, the first FDA-approved treatment for molluscum contagiosum in patients aged two years and older. They are also advancing VP-103 for plantar warts and have a license agreement for LTX-315 for dermatologic oncology indications.

Verrica Pharmaceuticals Inc. is headquartered in West Chester, Pennsylvania, United States, and primarily conducts its clinical trials there. They have engaged with European regulatory authorities and have a collaboration with Torii Pharmaceutical Co., Ltd. for development and commercialization in Japan.

Verrica Pharmaceuticals has maintained a generally positive brand reputation within the analyst community, holding a consensus rating of "Moderate Buy" with an average target price of $17.00. The company scored higher than 79% of companies evaluated by MarketBeat and ranked 194th out of 872 stocks in the medical sector. Management has expressed confidence, and the strong demand for YCANTH® dispensed applicator units in 2025, along with positive feedback from physicians, further contribute to a favorable reputation.

Verrica Pharmaceuticals Inc. has 38 institutional owners and shareholders, holding a total of 2,317,132 shares, including Caligan Partners LP, Armistice Capital, Llc, and Vanguard Group Inc. Individual insiders who own company stock include Jayson Rieger (President and CEO), Paul B. Manning (Chairman of the Board), and David Zawitz (Chief Operating Officer).